Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
Jeffrey Laurence(Hebrew University of Jerusalem), Cynthia M. Magro(Cornell University), Alexandra C. Racanelli, Dana Zappetti(Cornell University), J. Justin Mulvey(Memorial Sloan Kettering Cancer Center), Joanna Harp(Cornell University), Madhav Seshadri(Cornell University), Edward J. Schenck(Cornell University), Evelyn M. Horn(Cornell University)
Cited by 128
Related Papers
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
|Translational research|2020|2.3k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza
|JAMA Neurology|2020|928
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
|JAMA Internal Medicine|2020|555